### The Rise in Stimulant Prescribing

September 2025

Matthew J. Strait
Deputy Assistant Administrator
DEA Diversion Control Division

#### Disclaimer



The contents of this document do not have the force and effect of law and are not meant to bind the public or DEA in any way.

This document is intended only to provide clarity to the public regarding existing requirements under the law or agency policies.

I have no financial relationship to disclose.

#### Copyright Disclaimer



"The presentation is for educational purposes.

Materials, images, or sounds authored or created by parties other than DEA may be subject to copyright and are used herein in accordance with the fair use provision of Title 17 United States Code Section 107. DEA's use of these materials does not authorize persons outside of DEA further distribute of use copyrighted materials."

#### **THREAT**




## Virtually all U.S. regions have experienced rising overdose death rates over the past two decades.

- 107,543 reported deaths in 2023
- 82,000 from opioids (prescription and illicit)
- 87,000 predicted deaths (October 2023 September 2024)\*

<sup>\*</sup> CDC Press Release, February 25, 2025


#### TRAJECTORY OF THE U.S. OVERDOSE CRISIS





# CHARTING THE FOURTH WAVE: POLYSUBSTANCE TRENDS





Sources: CDC NVSS/WONDER; Friedman J, Shover CL. Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010-2021. Addiction. 2023 Dec;118(12):2477-2485. doi: 10.1111/add.16318. Epub 2023 Sep 13. PMID: 37705148.

#### **HOW DID WE GET HERE? 1980**



Vol. 302 No. 2

CORRESPO

#### ADDICTION RARE IN PATIENTS TREATED WITH NARCOTICS

To the Editor: Recently, we examined our current files to determine the incidence of narcotic addiction in 39,946 hospitalized medical patients who were monitored consecutively. Although

We conclude that despite widespread use of narcotic drugs in hospitals, the development of addiction is rare in medical patients with no history of addiction.

JANE PORTER
HERSHEL JICK, M.D.
Boston Collaborative Drug
Surveillance Program
Boston University Medical Center

Waltham, MA 02154

1. Jick H, Miettinen OS, Shapiro S, Lewis GP, Siskind Y, Slone D. Comprehensive drug surveillance. JAMA. 1970; 21391455-60.

 Miller RR, Jick H. Clinical effects of meperidine in hispitalized medical patients. J Clin Pharmacol. 1978; 18:180-8.


#### THE FIFTH VITAL SIGN



1990 – Initiated by the American Pain Society

2001 – Joint Commission (JCAHO) introduced standards to improve the care of patients in pain


- 1.Temperature
- 2.Heart Rate
- 3.Blood Pressure
- 4. Respiration
- 5.Pain



Source: Joint Commission


#### **EXPLOITATION OF THE INTERNET - 2005**





#### **COMPETITION – FDA DRUG APPROVALS**






Source: FDA Orange Book, retrieved March 10, 2021

#### FDA DRUG APPROVALS






Source: FDA Orange Book, retrieved March 13, 2025


#### TREATMENT - BUPRENORPHINE






#### STIMULANT USE






# STIMULANT PRESCRIBING INCREASING IN ADULTS






#### STIMULANT PRESCRIBERS BY SPECIALTY





#### DTC MARKETING - SOCIAL MEDIA





Online Mental Health Companies

How Untreated ADHD Ruins

Some employees and patients say these marketing practices have contributed to the abuse of controlled substances

THE WALL STREET JOURNAL.

#### **EASY ACCESS VIA TELEMEDICINE**



#### **Brightside** Health

Individual Therapy Medication Management

Treatment for anxiety, depression, & insomnia

\$95 - \$349 monthly

Insurance Accepted

Video or Phone Sessions Texting between sessions

Medication Prescribed

#### Cerebral ▼

Individual Therapy
Medication Management


Treatment for anxiety, depression, ADHD, insomnia, addictions, & more

\$99 - \$325 monthly

Insurance Accepted

Video or Phone Sessions Texting between sessions

Medication Prescribed






# Drug Shortages for Controlled Substances

	March 2024	March 2025
<b>Total Presentations</b>	1894	1944
<b>Total CS Presentations</b>	396 (21%)	443 (23%)
Lisdexamfetamine	87	100
Amphetamine	73	73
Methylphenidate	39	55
Morphine	29	29
Hydromorphone	22	27
Fentanyl	20	30
Remifentanil	9	9
Sufentanil	4	4
Oxycodone	3	
Methamphetamine	2	2


80% of schedule II stimulants listed as being in Shortage are either:

- available
- limited availability



#### TIME AND SPACE FOR CRIMINAL ORGANIZATIONS





## Top Ten Pill Imprints Seen As Counterfeits by Pill Count (Select Image to View Stats for the Imprint)

168,856,886


Counterfeit Pill Count

36,184

Counterfeit Exhibit Count



Reset All Filters



Source: DEA, extracted August 26, 2025

#### HALLMARKS OF A DRUG OVERDOSE EPIDEMIC



- ✓ Public Health Concern undertreatment of pain
- ✓ Free market forces competition, DTC advertising, social media
- ✓ Prescription growth, expansion
- ✓ Intervention Public Health and Public Safety Officials limits supply; drug shortages; expanding treatment options
- ✓ Transnational Criminal Organization Exploitation counterfeiting
- ✓ Lagging Use of Treatment Medications especially when they are controlled substances

## Thank You